Clinical trial
PR-104 and Docetaxel or Gemcitabine in Treating Patients With Solid Tumors
NCT00459836 · Proacta, Incorporated, Industry · Completed
Key facts
| NCT number | NCT00459836 |
|---|---|
| Title | PR-104 and Docetaxel or Gemcitabine in Treating Patients With Solid Tumors |
| Official title | A Phase Ib, Multi-Center, Open-Label, Dose Escalation Trial of Intravenous PR-104 Given in Combination With Docetaxel or Gemcitabine in Subjects With Solid Tumors |
| Lead sponsor | Proacta, Incorporated, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Unspecified Adult Solid Tumor, Protocol Specific |
| Intervention type | Drug, Other |
| Interventions | PR-104, docetaxel, gemcitabine hydrochloride, laboratory biomarker analysis, pharmacological study |
| Enrollment | 42 |
| Start date | Feb 1, 2007 |
| Primary completion | Oct 1, 2009 |
| First posted | Apr 13, 2007 |
| Last update posted | Mar 2, 2011 |
| Countries | New Zealand, United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: